Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.60 |
| ▸ | F2 | P00734 | 3/20 | 0.58 |
| ▸ | F5 | P12259 | 1/20 | 0.58 |
| ▸ | F9 | P00740 | 2/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.57 |
| ▸ | F7 | P08709 | 2/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14496715 | 1.00 | F10 (0.60) | F10F2F5F9PRSS1 | |
| Hydrochloric Acid SCHEMBL5542923 | 0.99 | F10 (0.60) | F10F2F5F9PRSS1 | |
| SCHEMBL5542847 | 0.95 | F10 (0.60) | F10F2F5F9PRSS1 | |
| SCHEMBL14496719 | 0.92 | F10 (0.59) | F10F2F5F9PRSS1 | |
| SCHEMBL14497112 | 0.92 | F10 (0.59) | F10F2F5F9PRSS1 | |
| Hydrochloric Acid SCHEMBL5543110 | 0.91 | F10 (0.58) | F10F2F5F9PRSS1 | |
| SCHEMBL14496722 | 0.91 | F10 (0.57) | F10F2F5F9PRSS1 | |
| SCHEMBL14496718 | 0.90 | F10 (0.59) | F10F2F5F9PRSS1 | |
| SCHEMBL14496724 | 0.90 | F10 (0.59) | F10F2F5F9PRSS1 | |
| SCHEMBL14497114 | 0.90 | F10 (0.59) | F10F2F5F9PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | F10 238/4885F2 11/4885F5 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.